Adaptive Biotechnologies Corp.
|Number of Estimates|
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.
Market Cap: 3.76 Billion
Primary Exchange: NASDAQ
Shares Outstanding: 124 Million
Float: 115 Million
Sector: Commercial Services
Industry: Miscellaneous Commercial Services
Longest drawdown: 84 trading days
From: 2019-09-04 To: 2019-12-13
|Ex-Date||Payment Date||Record Date||Declared Date||Amount||Flag||Dividend Type||Qualified||Indicated|
|Ex-Date||Declared Date||Record Date||Payment Date||Ratio||To Factor||For Factor|